A Canadian drug manufacturer recently announced that it will refund covered entities for hundreds of different products purchased between 2021 [...] …
Category: Pharma Industry
A Japanese drug manufacturer has ended its 340B contract pharmacy restrictions in Maryland and Mississippi in conjunction with new contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two major drug manufacturers are suing Minnesota to block a new 340B contract pharmacy access law, which took effect this [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
News Alert
Federal Judge Denies Drugmakers’ Bids to Block Mississippi’s New 340B Contract Pharmacy Access Law
A federal district judge has rejected two drug industry attempts to block Mississippi’s new state law prohibiting drugmaker 340B contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Missouri Gov. Mike Parson (R) has less than two weeks to decide the fate of a 340B contract pharmacy access [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Canonsburg, Penn.-based Viatris yesterday became the 37th drugmaker to restrict the shipment of 340B-priced drugs in the contract pharmacy setting. [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
More Drugmakers Exempt States from Contract Pharmacy Restrictions as Four New State Laws Take Effect
Four major drug manufacturers announced they will fully or partially exempt covered entities in certain states from their 340B contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Correction, Thursday, July 27, 2024, 7:00 p.m. EDT—The original version of this article mistakenly said Minnesota’s contract pharmacy access law [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Five new manufacturer restrictions on wholly-owned pharmacies taking effect in July will be “disastrous” for certain health center pharmacy arrangements, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Inflation Reduction Act (IRA) may reduce 340B margins for certain high-cost drugs and drive more transparency into the program, an influential pharmaceutical supply chain analyst who has been a frequent 340B critic told an audience of stakeholders late last
…